China Pharma Holdings Announces $5M Registered Direct Offering

What Happened

• China Pharma Holdings, Inc. announced on July 22, 2026 that it entered a securities purchase agreement to sell 2,500,000 shares of common stock at $2.00 per share in a registered direct offering for aggregate gross proceeds of $5,000,000. The closing is expected on or around July 23, 2026. FT Global Capital, Inc. is the exclusive placement agent for the offering.

Key Details

• Securities: 2,500,000 shares of common stock at $2.00 per share; total gross proceeds $5,000,000 (before fees and expenses).
• Placement agent: FT Global Capital, Inc.; cash commission equal to 7.0% of aggregate proceeds. FT Global also may earn the same commission for certain financings within 18 months involving investors it introduced.
• Investor rights and restrictions: the investor (an institutional accredited investor) has a right to participate in up to 40% of subsequent financings for three months after closing; the Company agreed not to enter into or announce most subsequent placements or variable rate transactions for 91 days after closing.
• Registration: Shares are offered under an effective Form S-3 shelf registration declared effective February 14, 2024.

Why It Matters

• This transaction provides China Pharma with immediate capital (about $5.0M gross) to fund operations or growth initiatives, while also binding the company to short-term limits on additional financings and certain transaction types. The 7% placement fee and the investor participation/right restrictions could affect the net proceeds and the Company's flexibility to raise capital in the near term. Investors should note the dilution from 2.5M new shares and the short-term financing constraints described in the 8-K.